MedTrace Logo

A Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

NCT04612517 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-09-02

No results posted yet for this study

Summary

This is a randomised, double-blind, placebo-controlled, multiple ascending dose trial in healthy subjects, randomised to ZP7570 or placebo within each cohort

Conditions

  • Healthy

Interventions

DRUG

ZP7570

Each subject will be randomly allocated to multiple doses of ZP7570 at one of four dose levels in each cohort.

DRUG

Placebo

Placebo; corresponding volume

Sponsors & Collaborators

Principal Investigators

  • Ulrike Hövelmann · Profil Institut für Stoffwechselforschung GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-26
Primary Completion
2021-08-30
Completion
2021-08-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04612517 on ClinicalTrials.gov